POTENTIAL DEAL DETAILS
|Stock||China Biologic Products Holdings, Inc.||Symbol||CBPO|
|Date Announced||09/18/2019||Source||Press Release|
|Type||Unsolicited Bid||Acquiring Company/Person||N/A|
China Biologic Products Holdings, Inc. (CBPO), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its board of directors has received a preliminary non-binding proposal letter, dated September 18, 2019.
Former CEO-led consortium previously approached China Biologic Products Holdings, Inc. (CBPO) on August 17, 2018. It was unsuccessful since the Company announced that the Board has unanimously decided to reject the announced preliminary non-binding proposal.
Disclaimer: Our intent with this section of the website is to present potential deals that appear to be in the pipeline. These potential deals are ones where i) the company has indicated that it is "seeking strategic alternatives", ii) there has been an unsolicited bid for a company as mentioned in a press release by the company or iii) news about the deal has been published by a leading news organization like The Wall Street Journal, The New York Times, Bloomberg, Financial Times, The Washington Post, Reuters and The Associated Press. As best as possible we will try to avoid baseless rumors. There is a high probability that many of these potential deals may not materialize and if they do, the terms of the deal may be different from what was initially reported. Please do your own due diligence before buying or selling any securities mentioned on this website. We do not warrant the completeness or accuracy of the content or data provided.